T. Kirkgoz Et Al. , "Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with 1-year IDeg/Asp Therapy in Poorly Controlled and Non-compliant Patients.," Journal of clinical research in pediatric endocrinology , vol.14, pp.10-16, 2022
Kirkgoz, T. Et Al. 2022. Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with 1-year IDeg/Asp Therapy in Poorly Controlled and Non-compliant Patients.. Journal of clinical research in pediatric endocrinology , vol.14 , 10-16.
Kirkgoz, T., Eltan, M., Kaygusuz, S. B., Yavas Abali, Z., Helvacioglu, D., Seven Menevse, T., ... Gurpinar Tosun, B.(2022). Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with 1-year IDeg/Asp Therapy in Poorly Controlled and Non-compliant Patients.. Journal of clinical research in pediatric endocrinology , vol.14, 10-16.
Kirkgoz, Tarik Et Al. "Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with 1-year IDeg/Asp Therapy in Poorly Controlled and Non-compliant Patients.," Journal of clinical research in pediatric endocrinology , vol.14, 10-16, 2022
Kirkgoz, Tarik Et Al. "Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with 1-year IDeg/Asp Therapy in Poorly Controlled and Non-compliant Patients.." Journal of clinical research in pediatric endocrinology , vol.14, pp.10-16, 2022
Kirkgoz, T. Et Al. (2022) . "Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with 1-year IDeg/Asp Therapy in Poorly Controlled and Non-compliant Patients.." Journal of clinical research in pediatric endocrinology , vol.14, pp.10-16.
@article{article, author={Tarik Kirkgoz Et Al. }, title={Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with 1-year IDeg/Asp Therapy in Poorly Controlled and Non-compliant Patients.}, journal={Journal of clinical research in pediatric endocrinology}, year=2022, pages={10-16} }